Daxor Corporation (NYSE Amex: DXR), a medical instrumentation and
biotechnology company, today announced that the Board of Directors has
voted to declare a dividend of $0.25 per share. The dividend will be
paid to shareholders of record as of Wednesday, September 15, 2010.
The dividend will be paid on Thursday, September 30, 2010.

This is the second dividend the Company has declared for 2010. The
Company paid a dividend of $0.10 per share on Wednesday, June 16,
2010.

These payments are in keeping with the declaration of Company
management in 2008 to pay dividends when funds are available.

For the year ended December 31, 2009, the Company paid a total
dividend of $1.35 per share as follows: $0.10 per share on June 15th,
$0.25 per share on September 8th and $1.00 per share on December 24,
2009.

As part of our ongoing research and development efforts, Daxor is
actively supporting several clinical trials in three strategic areas:
Critical Care Medicine, Heart Failure and Blood Loss During Surgery.
One study has recently been completed: Blood Volume Analysis in
treating Intensive Care Unit (ICU) Patients - A Prospective,
Randomized Outcome Study. The objective of this study was to
investigate whether inclusion of measured blood volume analysis using
Daxor's Blood Volume Analyzer (BVA-100) in the diagnosis and treatment
of ICU patients would result in (1) a change in their treatment; (2)
improved clinical outcomes; and (3) reductions in the cost of care. In
addition, two of Daxor's Heart Failure Investigators will present
their preliminary research findings at the annual Heart Failure
Society of America meeting which will take place in San Diego,
California from September 12-15, 2010.

Daxor Corporation is sponsoring a multi-center, prospective,
randomized clinical trial (TEAM-HF) which will compare heart failure
management strategies based on either standard clinical practices or
on direct blood volume measurement through the use of Daxor's BVA-100.
Dr. Stuart Katz, the Director of the Heart Failure Program at New York
University, will serve as the National Principal Investigator for this
study.

There are currently five million Congestive Heart Failure patients in
the United States. Heart Failure is the leading cause of hospital
admission in patients over 65 years of age. Medicare currently bases
reimbursement decisions on the patient's diagnosis regardless of how
many days a patient spends in a hospital. This creates a strong
financial incentive for hospitals to discharge patients as early as
possible for a given diagnosis. Medicare has become aware that
hospitals are discharging patients prematurely, before their treatment
is completed. In fact, twenty percent of heart failure patients are
readmitted to the hospital within 30 days, at which point the hospital
receives another round of reimbursement for the same condition.

Medicare is considering the implementation of new guidelines in which
hospitals do not get reimbursed for congestive heart failure patients
who are readmitted within 30 days of discharge. One hospital which has
purchased the BVA-100 recognizes this problem and has implemented a
policy in which the majority of patients admitted for congestive heart
failure must be diagnosed and treated on the basis of a blood volume
measurement. Such patients will also be given at least one subsequent
blood volume measurement prior to discharge to ensure that they are
not prematurely discharged.

The objective of TEAM-HF is to determine whether incorporation of
blood volume results into the diagnosis and treatment of heart failure
patients leads to decreased hospitalization and mortality, and an
improvement in exercise capacity and quality of life. This trial will
enroll 300 heart failure patients from 12 medical centers. If it can
be demonstrated in a large-scale study that blood volume analysis
leads to better patient outcomes, the BVA-100 may become a standard of
care in heart failure. Patient enrollment into this study is expected
to begin in the fourth quarter of 2010. This is the largest study
supported by Daxor to date.

Daxor Corporation manufactures and markets the BVA-100, the only
FDA-approved semi-automated Blood Volume Analyzer. The BVA-100 is used
in conjunction with Volumex, Daxor's single use diagnostic kit. For
more information regarding Daxor Corporation's Blood Volume Analyzer
BVA-100, visit Daxor's website www.Daxor.com (http://www.daxor.com/) .